Intercept Prescription drugs, Inc. ICPT dosed first affected person in a Part 2 examine evaluating a fixed-dose mixture of obeticholic acid (OCA) and bezafibrate (BZF) for the therapy of sufferers with major biliary cholangitis (PBC).
The examine is predicted to recruit roughly 60 sufferers in the USA.
Additional, a second Part 2 examine is presently lively in Europe, evaluating completely different dosing regimens of the OCA-BZF mixture.
M. Michelle Berrey, Chief Medical Officer, stated, ”We consider OCA and BZF have synergistic mechanisms of motion that may doubtlessly present extra advantages to folks with PBC when utilized in mixture. Moreover, each medicines have been proven to assist decrease the important thing biochemical measures that predict long-term outcomes in PBC. BZF has additionally been related to enhancements in pruritus, a possible profit we’re exploring in our Part 2 program.”
Within the on-going section 1 examine in the USA, wholesome grownup topics are being examined for various dosage combos.
Intercept Prescription drugs is presently buying and selling down at $18.58.